Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

2.030 +0.220 (+12.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Cabaletta Bio: Here's What You Need To Know
Via Benzinga
Where Cabaletta Bio Stands With Analysts
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 11/9
Via Investor Brand Network
Cabaletta Bio: Q3 Earnings Insights
Via Benzinga
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/24
Via Investor Brand Network
7 Analysts Have This to Say About Cabaletta Bio
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/23
Via Investor Brand Network
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
From Cellares
Via Business Wire
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
From Cabaletta Bio
Via GlobeNewswire
The Latest Analyst Ratings for Cabaletta Bio
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 9/12
Via Investor Brand Network
Analyst Ratings for Cabaletta Bio
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 8/23
Via Investor Brand Network
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 8/18
Via Investor Brand Network
HC Wainwright & Co. Maintains Buy Rating for Cabaletta Bio: Here's What You Need To Know
Via Benzinga
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
Why America's Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Verb Technology Company, Inc. (NASDAQ: VERB) shares jumped 164% to $1.89 after the completed and launched a technology integration and strategic relationship with global social media platform... 
Via Benzinga
Brady, Airbnb, Insmed And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023
Via Benzinga
The 7 Most Promising Momentum Stocks to Own Now
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. 
Via InvestorPlace
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.